Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer
Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AnastrozoleElacestrant+3
Austria- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group













